Chinese early-stage pharmaceutical firm Ractigen Therapeutics has announced the raising of 110 million yuan ($17 million) in its Series A round led by Asia-focused PE firm Hillhouse Capital’s venture unit GL Ventures, the investor announced on February 11.
Access this premium content with a DATA VANTAGE subscription
Learn more about DATA VANTAGEAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
